An electronic “nose” that measures various compounds in exhaled breath reliably distinguishes patients with epilepsy from controls, new research shows. The noninvasive diagnostic tool is faster, less costly, and less invasive than electroencephalography (EEG) — the standard technique to diagnose epilepsy. Patients simply insert a small hand-held device into their mouth and breath into it for 5 minutes.
Almost three quarters of patients with medically intractable seizures who received neurostimulation with a novel device called the RNS System (NeuroPace Inc) had sustained seizure reduction at 8 years, new research shows. Furthermore, the analysis found that almost a third of those receiving the RNS System had at least one 6-month period without seizures and that the treatment remained relatively safe over time.
Scientists from RUDN University took an active part in the development of a chemical compound to stop convulsions during epileptic seizures. The results of the study were published in Chirality. Epilepsy is a chronic neuralgic disease that causes convulsive seizures in humans and other animals. The pathogenesis of this disease is paroxysmal discharges in the nerve cells of the brain that cause convulsions. Anticonvulsants help to stop the epileptic fit. The drug itself is a powder that is dissolved in water and injected into a person experiencing such a seizure.
Approximately 30 per cent of patients with epilepsy do not respond to anti-epileptic drugs. In these cases, all neurologists can do is attempt to find the right combination of medication through trial and error. A treatment that could target the root cause of epilepsy is a beacon of hope for these patients. But identifying the cause of the pathology is no easy feat. “There are many genes involved,” said Jacques Michaud, pediatrician at CHU Sainte-Justine and Professor of Pediatrics and Neuroscience at the Faculty of Medicine of Université de Montreal. “Each child can have different genetic mutations. Often the clinical symptoms do not clearly reflect the cause of epilepsy, which makes choosing the right treatment more difficult.”
A new Danish study finds that people who suffer from psychogenic non-epileptic seizures (PNES) — a condition characterized by spasms similar to epileptic seizures but which are unexplained and untreatable — have a lower level of the hormone neuropeptide Y (NPY) in their blood. NPY is a hormone associated with an increased resilience for dealing with stress.
Aging is a fact of life for everyone. But thanks to advances in medical technology, medications, and tools that make living and workspaces more accessible, people can expect to stay in their homes for far longer today than they used to. Every year, more than one-fourth of adults 65 and older will take a fall. For those that do, the risk of a repeat fall is doubled. That doesn’t mean living at home is without its dangers. Every year, more than one-fourth of adults 65 and older will take a fall, according to the Centers for Disease Control. For those that do, the risk of a repeat fall is doubled. One out of five of these falls results in a serious injury to the head or other part of the body, while 95% of hip fractures are caused by falling.
Several new Australian-developed medicines showing promise treating childhood epilepsy, stroke and autoimmune diseases have emerged from an unusual source: the fangs of venomous creatures. Big pharmaceutical companies are excited by results showing these new venom-drugs are often superior to man-made drugs, and they are starting to pour money into research.
Seizure disorders — including epilepsy — are associated with pathological hyperexcitability in brain neurons. Unfortunately, there are limited available treatments that can prevent this hyperexcitability. However, University of Alabama at Birmingham researchers have found that inducing a biochemical alteration in brain proteins via the dietary supplement glucosamine was able to rapidly dampen that pathological hyperexcitability in rat and mouse models. These results, seen in animal models, represent a potentially novel therapeutic target for the treatment of seizure disorders.
Patent Covers Key Biomarkers in Evogen’s EvoScoreDX™ Biomarker-Based Blood Test for Distinguishing Epileptic Seizures; Addresses Major Unmet Need for Better Epilepsy Diagnostics Evogen, Inc., a leader in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, today reported that the U.S. Patent and Trademark Office (USPTO) has issued a key patent covering the company’s biomarker-based blood test that can accurately identify epileptic seizures. It is the first patent to issue in Evogen’s multi-application intellectual property portfolio of blood-based biomarkers for seizure detection in epilepsy and other neurological diseases. U.S. Patent No. 9,772,335 is owned by the University of Pennsylvania (Penn) and is exclusively licens...
While a number of studies have suggested that marijuana may be effective for reducing seizures, new research cautions that potent and synthetic forms of the drug have the opposite effect. Researchers from the University of Tsukuba in Japan found that natural tetrahydrocannabinol (THC) – the psychoactive chemical in marijuana – and the synthetic cannabinoid JWH-018 caused seizures in mice. Study leader Olga Malyshevskaya and colleagues say that their findings – which are published in the journal Scientific Reports – should serve as a “public alert” to the potential harms caused by high-potency and synthetic marijuana.
When people see an image of a person they recognize—the famous tennis player Roger Federer or actress Halle Berry, for instance—particular cells light up in the brain. Now, researchers reporting in Current Biology on September 21 have found that those cells light up even when a person sees a familiar face or object but fails to notice it. The only difference in that case is that the neural activity is weaker and delayed in comparison to what happens when an observer consciously registers and can recall having seen a particular image.
Armed with a 3D printer and bio-ink made from stem cells, Australian scientists have created brain-like tissue in a breakthrough research. The unique bio-ink is composed of human induced pluripotent stem cells (iPSC) – possessing the same properties as embryonic stem cells – capable of transforming into any cell (and organ) in the body.